Deutsche Bank raised the firm’s price target on Genmab (GMAB) to DKK 1,900 from DKK 1,750 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
- Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity
- Genmab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Genmab price target raised to $36 from $35 at H.C. Wainwright
- Genmab’s Tisotumab Vedotin Study: A Promising Update for Solid Tumor Treatment